Annual screening may be framed as readiness policy, but doctors warn that unclear implementation and inappropriate treatment could create avoidable health and fertility risks.

Medical specialists are questioning the evidence behind a Pentagon plan for annual testosterone-deficiency screening for US service members aged 30 and over, warning that the policy lacks clear implementation guidance and could lead to unnecessary treatment.

The scrutiny was reported by Reuters on 18 July, after the US Defence Department issued an order earlier in the week. The policy is framed around force health and readiness, but independent doctors told Reuters that broad screening of asymptomatic personnel is not supported by standard medical guidance.

The issue matters because military health policy is operational policy. Service members’ physical condition affects readiness, deployability, retention and long-term healthcare costs. But a screening programme can create harm if it identifies borderline results without symptoms, encourages unnecessary medication or fails to explain risks.

Testosterone levels vary by time of day, illness, sleep, stress, body weight, medication and testing method. A low reading does not automatically mean a clinically meaningful deficiency. Medical societies generally recommend testing when symptoms suggest a problem, not universal screening of large populations without clear clinical indications.

The treatment risk is also important. Testosterone therapy can suppress sperm production and affect fertility. It can also require monitoring for cardiovascular, prostate, blood-count and hormonal effects. For service members who want children, inappropriate treatment could create personal consequences not captured by a readiness slogan.

The Pentagon may argue that early detection supports resilience, physical performance and mental health. Those are legitimate military concerns. But readiness medicine must still meet evidence standards. A programme that produces large numbers of referrals, repeat tests and prescriptions without clear benefit can consume medical capacity and expose personnel to risk.

Implementation is likely to be difficult. The services would need rules on who is tested, when blood is drawn, what thresholds trigger follow-up, how symptoms are assessed, which clinicians can prescribe treatment and how fertility counselling is handled. Without that detail, annual screening could become inconsistent across bases.

Defence Matters has often covered readiness through equipment, procurement and force posture. This case shows that readiness also depends on medical governance. A poorly designed health policy can affect personnel just as surely as a shortage of spare parts affects aircraft.

The policy also raises consent questions. Service members are not ordinary patients because military structures involve command authority, fitness standards and career consequences. Personnel may worry that refusing treatment or recording a medical issue could affect promotion, deployment or retention. That makes clear information and safeguards essential.

There is also a cultural risk. Testosterone has become politically and commercially charged, especially in online wellness and masculinity markets. A military screening policy could unintentionally reinforce non-medical narratives about strength and performance unless it is tightly grounded in clinical evidence.

The Pentagon should therefore publish detailed guidance and the evidence base behind the order. If screening is meant to address specific readiness problems, those problems should be quantified. If treatment is voluntary and symptom-based, that should be explicit.

The debate is not about dismissing service members’ health concerns. It is about ensuring that a universal programme does not turn a real medical condition into an overbroad intervention. In military medicine, as in combat systems, readiness claims need testing before they are scaled.

The policy also has resource implications. Annual testing for a large population of service members would create laboratory demand, follow-up appointments and specialist referrals. If many results are borderline or transient, the system could generate workload without improving deployability.

Defence Matters has recently examined readiness through NATO force posture and equipment availability, including the debate over US deployments on the eastern flank. Medical readiness is part of the same operational picture. A force is not ready simply because policy says it is; readiness requires evidence, logistics and careful implementation.

The Pentagon can still make a stronger case if it publishes data showing a significant undiagnosed problem among service members over 30 and explains how screening will be tied to symptoms, counselling and voluntary treatment. Until then, doctors’ concerns deserve to be treated as a readiness warning, not bureaucratic resistance.